IL1RL2 and neoplasm: To evaluate antitumor effects of the IL-36/IL-36R signaling axis systematically, we examined an expansive set of preclinical tumor models representing different genetic backgrounds, diverse TMEs, and varied responses to cancer immunotherapies.